Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-04-30

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to observe transient dyspnea pattern after Gd-EOB-DTPA administration by obtaining continuous dynamic T1 weighted image data.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia

NCT00209456

Lewy Body Dementia Non-DLB Dementia Alzheimer's +1 more

COMPLETED PHASE3

High Resolution HBA-MRI Using Deep Learning Reconstruction

NCT05182099

Liver Diseases Magnetic Resonance Imaging Deep Learning

UNKNOWN NA

Gadopiclenol vs Gadoxetate MRI for Liver Lesions

NCT06596616

Liver Lesion

ENROLLING_BY_INVITATION

7.0T Magnetic Resonance Imaging Study for Hepatic Encephalopathy

NCT06923254

Hepatic Encephalopathy (HE) MRI fMRI Research

NOT_YET_RECRUITING

Evaluation of a New MRI Technique to Reduce Breathing-Related Artifacts in Brain Imaging

NCT07305948

Brain Diseases

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyspnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observe1

Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)

gadoxetic acid

Intervention Type DRUG

standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration

Magnetic resonance imaging (MRI)

Intervention Type OTHER

Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.

precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

gadoxetic acid

standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration

Intervention Type DRUG

Magnetic resonance imaging (MRI)

Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.

precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

eovist primovist

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are referred to MR unit for hepatocyte-specific contrast enhanced liver MRI using gadoxetic acid, to characterize focal liver lesion or to investigate diffuse liver disease
* OR, Liver living donor candidates
* AND subjects who sign the informed consent.